GraniteShares 2x Long INTC Daily ETF (NASDAQ: INTW)

에 대한 최신 뉴스 GraniteShares 2x Long INTC Daily ETF (NASDAQ:INTW)

Technology

The Fund is an actively managed exchange traded fund that attempts to replicate 2 times (200 percent) the daily percentage change of the Underlying Stock by entering into financial instruments such as swaps and options on the Underlying Stock as well as directly purchasing the Underlying Stock. At the end of each trading day, the notional exposure against the Underlying Stock obtained through the combination of these instruments will be approximately 200 percent of the Funds net asset value. The Fund aims to generate the inverse daily performance of the Underlying Stock for a single day. A single day is defined as being calculated from the close of regular trading on one trading day to the close on the next trading day.

Intel Corp.

GraniteShares 2x Long INTC Daily ETF

Top 5 Gold ETFs To Shield Your Portfolio From Rising Inflation

Broad U.S. Equity ETFs

ETFs

INTC

INTW

NVDA

ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF

NVDX

SMCI

SMCX

예상보다 부진한 인플레이션 지표가 연준 금리 인하에 대한 기대감을 높였지만, 시장은 여전히 백악관의 정책 불확실성에 머물러 있다. 하지만 전반적인 시장 약세에도 불구하고 지난주 일부 ETF는 다른 종목보다 더 좋은 성과를 보였다.

미국 증시 하락세에도 불구하고 상승한 ETF 5종목

SHARC INTL SYS INC by Sharc International Systems Inc.

Sharc International Systems Inc

Rosenblatt analyst Kevin Cassidy maintains Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral and maintains $3 price target.

News

Price Target

Analyst Ratings

BZAI

Rosenblatt Maintains Neutral on Blaize Holdings, Maintains $3 Price Target

Investar Holding Corporation ("Investar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>), the holding company for Investar Bank, N.A., and Wichita Falls Bancshares, Inc. ("Wichita Falls"), the holding company for First National Bank, Wichita Falls, Texas, jointly announced today that they have entered into a definitive agreement pursuant to which Investar will acquire Wichita Falls for cash and stock consideration. In connection with the proposed acquisition, Investar also announced today a private placement of $32.5 million of its newly designated 6.5% Series A Non-Cumulative Perpetual Convertible Preferred Stock.
The definitive agreement has been unanimously approved by the boards of directors of Investar and Wichita Falls, and the closing of the transaction, which is expected to occur in the fourth quarter of 2025, is subject to customary conditions, including shareholder and regulatory approvals. The definitive agreement provides that upon the closing of the transaction, Wichita Falls shareholders will be entitled to receive an aggregate of 3,955,334 shares of Investar common stock, and cash consideration of $7.2 million, in exchange for their shares, subject to adjustment under certain circumstances. Based on the closing price of $19.32 for Investar common stock on June 30, 2025, the transaction would result in aggregate consideration of approximately $83.6 million, or $134.67 per share of Wichita Falls common stock.
&nbsp;

ISTR

Investar Holding Corporation Announced Merger with Wichita Falls Bancshares

PSEC

Prospect Capital Closes $115M All-Cash Acquisition Of QC Holdings; Company To Remain Headquartered In Kansas Under Existing Leadership

BLCO

Bausch + Lomb Uses Survey Insights And Patient Input To Clarify Dry Eye Realities

Adagene Inc. ("Adagene or the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext: SAN FP).
Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized phase 2 trial in microsatellite stable colorectal cancer (MSS CRC).
To further explore the clinical potential of muzastotug, Adagene will supply Sanofi with muzastotug to evaluate the safety, efficacy, pharmacokinetics and biomarker data in combination with other anticancer therapies in over 100 patients in a phase 1/2 clinical trial in advanced solid tumors. Adagene continues to own worldwide commercial rights to muzastotug.
Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene's proprietary masking technology and antibody engineering expertise. The bispecific therapeutic, with undisclosed targets, will be engineered by Adagene and induces an option exercise fee, as well as milestones and royalties as per the 2022 partnership agreement with Adagene.

ADAG

Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials

NVCR

Novocure To Present Final PANOVA-3 Secondary Data At ESMO GI 2025; TTFields Shows Pain Relief, QoL Gains In Pancreatic Cancer

<ul>
<li>Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI.</li>
<li>Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN</li>
<li>Non-dilutive financing further strengthens Apellis' balance sheet</li>
<li>Apellis retains full U.S. commercialization rights for systemic pegcetacoplan</li>
<li>Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases</li>
</ul>

Biotech

Health Care

Contracts

General

APLS

Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)

QBTS

D-Wave Completes $400M ATM Equity Offering; Explores Strategic Acquisitions To Expand Quantum Leadership

ZCAR

Zoomcar Partners With CARS24 To Bring Vehicle Inspection And Tracking Standards To Self-Drive Car-Sharing Space

Nokia today announced its latest venture, Enscryb, an energy innovation platform, is partnering with NODES, an energy trading company. In addition, Enscryb has also secured and onboarded two customers: Nanuq, a charging infrastructure company, and Smartecon, a renewable energy provider.

Nokia Announced Enscryb Partnership With NODES For Energy Innovation Platform; Onboards Nanuq And Smartecon As Initial Customers

TLRY

Tilray-Owned Breckenridge Distillery Debuts New Collectors Art Series Bottle Featuring Calvados Cask Finish And Toland Mural

<ul>
<li>Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.</li>
<li>Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH&#xAE; (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025.</li>
<li>Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget.</li>
<li>Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market.</li>
<li>Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025.</li>
<li>Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan</li>
</ul>

VRCA

Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts

Establishes Digital Computing Division to Drive Company's Digital Infrastructure Strategy, Adds Hash Rate of 3.11 EH/s, Expects Significant Bitcoin Mining Revenue, Sets Stage for Future High-Performance Computing (HPC) and AI-driven Entertainment Services Opportunities
ABU DHABI, United Arab Emirates, July 01, 2025 (GLOBE NEWSWIRE) -- NIP Group Inc. ("NIPG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced it has entered into a definitive asset-purchase agreement (the "Agreement") to acquire on-rack crypto mining machines (the "Products") from Fortune Peak Limited and Apex Cyber Capital Limited (together, the "Sellers"). These Products are currently used for Bitcoin mining and are expected to begin generating significant Bitcoin mining revenue for the Company upon closing of the acquisition. To support this initiative, NIPG has established a dedicated Digital Computing Division to manage the operations of the acquired Products and lead the future development of the Company's compute infrastructure capabilities. Importantly, this transaction marks a strategic extension of NIPG's business into the digital infrastructure space.
The Products, consisting of data center capacity with a combined hash rate of 3.11 EH/s, are currently utilized for Bitcoin mining operations with expected production of approximately 60 Bitcoins per month, and will continue operating immediately after closing of the proposed transaction. Under the terms of the Agreement, NIPG will pay the consideration for the Products through issuance of approximately 119,553,439 Class A ordinary shares of the Company to the Sellers. In connection with the consummation of the proposed transactions contemplated by the Agreement, the Company and the Sellers will also enter into an investor rights agreement to define certain rights and obligations among them with respect to the Company.
The closing of the proposed transaction is expected to occur on or before September 30, 2025, and is subject to customary closing conditions. There can be no assurance that the closing conditions will be satisfied nor that the proposed transaction will be completed before that date or at all.

NIPG

NIP Group Enters Into Definitive Asset-Purchase Agreement To Acquire On-Rack Crypto Mining Machines From Fortune Peak Limited And Apex Cyber Capital Limited

NIVF

NewGen Subsidiary Secures UAE Beachfront Plot; Explores Real World Asset Tokenization Amid $45M Real Estate Push

EDAP TMS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TMS S.A. (the "Company") currently qualifies as a foreign private issuer under applicable U.S. Securities and Exchange Commission ("SEC") rules and regulations. Effective January 1, 2026, the Company will no longer qualify for foreign private issuer status and will begin complying with and reporting under SEC reporting and other rules and Nasdaq listing requirements applicable to U.S. domestic filers, including, but not limited to, requirements with respect to the composition of the Company's board of directors and committees, certain corporate governance matters and shareholder approval of certain actions.

Government

Regulations

EDAP

EDAP TMS Will No Longer Qualify as Foreign Issuer, Adopts US Reporting Rules

Digital Realty Reaches 1.5 GW Of Renewable Energy Capacity Under Contract And Matching 185 Data Centers With 100% Renewable Energy

Management

JBIO

Jade Biosciences Appoints Brad Dahms As Chief Financial Officer

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs,&nbsp;today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy.
Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and industry and has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a significant BARDA contract as principal investigator, culminating in successful completion of the award. Earlier in his career, he held key R&amp;D leadership roles at Amgen, where he directed oncology and vascular biology drug discovery at the company's Washington research site.
 &nbsp;

Avacta Appoints Dr. David Liebowitz as Chief Medical Officer to Lead Cancer Drug Strategy

INVX

Innovex Completes All-Cash Divestment Of Subsea Tree Product Line To Trendsetter Engineering

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

Reiteration

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

지난주 <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44341328/stocks-enter-correction-zone-tariff-fears-hammer-consumer-confidence-inflation-worries-hit-32-year-highs-this-week-in-markets" target="_blank" rel="noopener">미국 증시는 4주 연속 하락세</a>로 마감하며 2022년 5월 이후 최장 하락을 기록했다.
S&amp;P 500 지수는 2월 고점 대비 10% 하락하며 조정 영역에 진입했다. 투자자들은 무역 긴장과 정부 지출 삭감에 대한 불안감이 계속되고 있다. 예상보다 부진한 인플레이션 지표가 연준 금리 인하에 대한 기대감을 높였지만, 시장은 여전히 백악관의 정책 불확실성에 머물러 있다.
하지만 전반적인 시장 약세에도 불구하고 지난주 일부 ETF는 다른 종목보다 더 좋은 성과를 보였다.
<h3 class="wp-block-heading">수익률 상위 5개 ETF</h3>
다음 ETF들은 광범위한 시장 변동성 속에서도 기회를 강조하고 있다.
GraniteShares 2x Long INTC Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTW#NASDAQ">INTW</a>): <a href="https://www.benzinga.com/etfs">레버리지 ETF</a>이며, 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 주식이 AI 지원 칩 수요에 대한 기대감 속에서 다시 상승세를 보이자 급등했다.
<ul>
<li>주간 수익률: 32.71%</li>
<li>운용수수료: 1.3%</li>
</ul>
Defiance Daily Target 2X Long SMCI ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCX#NASDAQ">SMCX</a>): 강력한 실적과 증가하는 AI 서버 수요에 의해 촉발된 슈퍼마이크로컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) 주가 상승은 이 ETF의 수익률을 끌어올렸다.
<ul>
<li>주간 수익률: 17.62%</li>
<li>운용수수료: 1.29%</li>
</ul>
T-Rex 2X Inverse Ether Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ETQ#BATS">ETQ</a>): 암호화폐 하락에서 이익을 얻는 이 인버스 ETF는 이더리움 가격 하락 덕분에 상승했다.
<ul>
<li>주간 수익률: 15.85%</li>
<li>운용수수료: 1.25%</li>
</ul>
T-Rex 2X Long NVIDIA Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NVDX#BATS">NVDX</a>): 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI 칩 시장에서의 지속적인 지배력은 이 레버리지 ETF를 상승시켰다.
<ul>
<li>주간 수익률: 14.62%</li>
<li>운용수수료: 1.05%</li>
</ul>
Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>): 경제 불확실성 시 안전 자산 수요로 인한 은 가격 상승은 은 광산주와 이 ETF를 상승시켰다.
<ul>
<li>주간 수익률: 8.82%</li>
<li>운용수수료: 0.65%</li>
</ul>
<h2 class="wp-block-heading">지난주 시장을 움직인 요인</h2>
트럼프 대통령의 무역 관세 보류와 일론 머스크의 정부효율부가 주도한 갑작스러운 지출 삭감으로 인해 투자자들의 불안감이 고조되고 있다. 2월 CPI 는 전년 동월 대비 2.8% 상승하여 컨센서스 2.9%보다 낮았지만, 이렇게 예상보다 완만한 인플레이션 수치에도 시장은 백악관의 정책 조치에 집착하고 있다.
트럼프는 EU가 미국산 위스키에 대한 50%의 관세를 인하하면 유럽산 와인에 200%의 관세를 부과하고 캐나다산 철강과 알루미늄에 대한 관세를 두 배로 올리겠다고 공언하며, 자동차 관세도 위협했다.
지난주 소비자 심리지수가 하락하고 장기 인플레이션 기대치가 1993년 이후 최고치를 기록했다. 경제 불확실성에 따라 <a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44335436/gold-etfs-shine-as-spot-price-tops-3000-during-safe-haven-demand" target="_blank" rel="noopener">금 가격은 온스당 3,000달러를 기록했으며</a> 지난 11주 중 10주 동안 상승했다.
지난 주말에는 정부 셧다운을 피할 수 있다는 확인과 새로운 무역 뉴스의 부재로 시장이 소폭 반등했다. 이번 주 연준 FOMC 회의에서는 금리동결이 예상되지만, 인플레이션이 지속되는 가운데 성장 둔화인 스태그플레이션에 대한 우려가 커지고 있다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

GraniteShares 2x Long INTC Daily ETF

뉴스

에 대한 최신 뉴스 GraniteShares 2x Long INTC Daily ETF (NASDAQ:INTW)

화요일, 3월 18, 2025

뉴스

파트너 / 기고자

벤징가 글로벌